GenoFocus Inc (187420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GenoFocus Inc (187420) has a cash flow conversion efficiency ratio of 0.005x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩288.09 Million ≈ $195.23K USD) by net assets (₩54.75 Billion ≈ $37.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GenoFocus Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how GenoFocus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GenoFocus Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
GenoFocus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GenoFocus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
0.000x |
|
ADVENICA AB
F:65R
|
0.098x |
|
PW Consolidated Bhd
KLSE:7134
|
0.093x |
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
0.040x |
|
Nimbus Group AB
ST:BOAT
|
-0.005x |
|
Selva Gida Sanayi AS
IS:SELVA
|
-0.049x |
|
Huvitz Co. Ltd
KQ:065510
|
-0.009x |
|
Arrienda Rental Properties SOCIMI SA
MC:YARP
|
0.052x |
Annual Cash Flow Conversion Efficiency for GenoFocus Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of GenoFocus Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see GenoFocus Inc (187420) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩54.75 Billion ≈ $37.10 Million |
₩3.50 Billion ≈ $2.37 Million |
0.064x | -47.00% |
| 2024-12-31 | ₩23.77 Billion ≈ $16.11 Million |
₩2.87 Billion ≈ $1.95 Million |
0.121x | +166.11% |
| 2023-12-31 | ₩26.36 Billion ≈ $17.87 Million |
₩-4.82 Billion ≈ $-3.26 Million |
-0.183x | +7.37% |
| 2022-12-31 | ₩23.89 Billion ≈ $16.19 Million |
₩-4.71 Billion ≈ $-3.19 Million |
-0.197x | -191.01% |
| 2021-12-31 | ₩35.28 Billion ≈ $23.91 Million |
₩-2.39 Billion ≈ $-1.62 Million |
-0.068x | -9.88% |
| 2020-12-31 | ₩39.77 Billion ≈ $26.95 Million |
₩-2.45 Billion ≈ $-1.66 Million |
-0.062x | -1818.94% |
| 2019-12-31 | ₩52.12 Billion ≈ $35.32 Million |
₩-167.50 Million ≈ $-113.51K |
-0.003x | -112.37% |
| 2018-12-31 | ₩60.21 Billion ≈ $40.80 Million |
₩1.56 Billion ≈ $1.06 Million |
0.026x | +22.28% |
| 2017-12-31 | ₩64.22 Billion ≈ $43.52 Million |
₩1.36 Billion ≈ $924.25K |
0.021x | +157.26% |
| 2016-12-31 | ₩62.52 Billion ≈ $42.37 Million |
₩516.09 Million ≈ $349.74K |
0.008x | -91.38% |
| 2015-12-31 | ₩29.79 Billion ≈ $20.19 Million |
₩2.85 Billion ≈ $1.93 Million |
0.096x | +423.17% |
| 2014-12-31 | ₩9.66 Billion ≈ $6.55 Million |
₩-286.45 Million ≈ $-194.12K |
-0.030x | -- |
About GenoFocus Inc
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phy… Read more